Non-high density lipoprotein cholesterol and coronary events during long-term statin treatment [1]

Atherosclerosis

Volumn 168, Issue 2, 2003, Pages 397-398

  Athyros, Vasilios G ^a   Papageorgiou, Athanasios A ^b   Symeonidis, Athanasios N ^c   Elisaf, Moses ^d  

^a Atherosclerosis Unit   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Greek Soc of General Practitioners   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CORONARY RISK; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DRUG EFFECT; DRUG RESPONSE; DRUG TARGETING; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LETTER; LIPID ANALYSIS; LIPID BLOOD LEVEL; MEDICAL ASSESSMENT; MORBIDITY; MORTALITY; NONBIOLOGICAL MODEL; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; SCREENING TEST; TITRIMETRY; TREATMENT OUTCOME;

EID: 0037834856     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00128-X     Document Type: Letter

References (7)

1. Pedersen T.R., Olsson A.G., Faergeman O., Kjekshus J., Wedel H., Berg K. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian simvastatin survival study (4S). Circulation. 97:1998;1453-1460.
2. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J. Am. Med. Assoc. 2001;285:2486-2497.
3. Cui Y., Blumenthal R.S., Flaws J.A., Whiteman M.K., Langenberg P., Bachorik P.S. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch. Intern. Med. 161:2001;1413-1419.
4. Frost P.H., Havel R.J. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am. J. Cardiol. 81:(Suppl 1):1998;26B-31B.
5. Bittner V., Hardison R., Kelsey S.F., Weiner B.H., Jacobs A.K., Sopko G. Non-high-density lipoprotein Cholesterol levels predict five-year outcome in the bypass angioplasty revascularization investigation (BARI). Circulation. 106:2002;2537-2542.
6. Lu W., Resnick H.E., Jablonski K.A., Jones K.L., Jain A.K., Howard W.J. Non-HDL Cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The Strong Heart Study. Diabetes Care. 26:2003;16-23.
7. Athyros V.G., Papageorgiou A.A., Mercouris B.R., Athyrou V.V., Symeonidis A.N., Basayannis A.C. Treatment with atorvastatin to the national cholesterol educational program goals versus usual care in secondary coronary heart disease prevention: The Greek atorvastatin and coronary-heart-disease evaluation (GREACE) study. Curr. Med. Res. Opin. 18:2002;220-228.